Intermittent theta burst stimulation vs. high-frequency repetitive transcranial magnetic stimulation for major depressive disorder: A systematic review and meta-analysis. 2023

Taro Kishi, and Kenji Sakuma, and Yuki Matsuda, and Shinsuke Kito, and Nakao Iwata
Department of Psychiatry, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi 470-1192, Japan. Electronic address: tarok@fujita-hu.ac.jp.

Our meta-analysis demonstrated that intermittent theta burst stimulation (iTBS)/bilateral-TBS (Bi-TBS) and high-frequency repetitive transcranial magnetic stimulation (HF-rTMS)/bilateral-rTMS (Bi-rTMS) had similar efficacy, acceptability, and safety profiles for antidepressant treatment-resistant major depressive disorder (AD-TRD). In our sensitivity analysis that excluded a study that compared Bi-TBS with Bi-rTMS for older adults, all efficacy outcomes were also comparable between iTBS and HF-rTMS. Because iTBS does not require higher stimulation intensity and a longer stimulus time than conventional HF-rTMS protocols, we speculated that for those with AD-TRD, iTBS/Bi-TBS is a more helpful therapeutic modality in clinical practice than HF-rTMS/Bi-rTMS.

UI MeSH Term Description Entries
D003865 Depressive Disorder, Major Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5) Depression, Involutional,Major Depressive Disorder,Melancholia, Involutional,Paraphrenia, Involutional,Psychosis, Involutional,Depressive Disorders, Major,Involutional Depression,Involutional Melancholia,Involutional Paraphrenia,Involutional Paraphrenias,Involutional Psychoses,Involutional Psychosis,Major Depressive Disorders,Paraphrenias, Involutional,Psychoses, Involutional
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000928 Antidepressive Agents Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. Antidepressant,Antidepressant Drug,Antidepressant Medication,Antidepressants,Antidepressive Agent,Thymoanaleptic,Thymoanaleptics,Thymoleptic,Thymoleptics,Antidepressant Drugs,Agent, Antidepressive,Drug, Antidepressant,Medication, Antidepressant
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D050781 Transcranial Magnetic Stimulation A technique that involves the use of electrical coils on the head to generate a brief magnetic field which reaches the CEREBRAL CORTEX. It is coupled with ELECTROMYOGRAPHY response detection to assess cortical excitability by the threshold required to induce MOTOR EVOKED POTENTIALS. This method is also used for BRAIN MAPPING, to study NEUROPHYSIOLOGY, and as a substitute for ELECTROCONVULSIVE THERAPY for treating DEPRESSION. Induction of SEIZURES limits its clinical usage. Transcranial Magnetic Stimulation, Paired Pulse,Transcranial Magnetic Stimulation, Repetitive,Transcranial Magnetic Stimulation, Single Pulse,Magnetic Stimulation, Transcranial,Magnetic Stimulations, Transcranial,Stimulation, Transcranial Magnetic,Stimulations, Transcranial Magnetic,Transcranial Magnetic Stimulations
D061218 Depressive Disorder, Treatment-Resistant Failure to respond to two or more trials of antidepressant monotherapy or failure to respond to four or more trials of different antidepressant therapies. (Campbell's Psychiatric Dictionary, 9th ed.) Refractory Depression,Therapy-Resistant Depression,Treatment Resistant Depression,Depression, Refractory,Depression, Therapy-Resistant,Depression, Treatment Resistant,Depressions, Refractory,Depressions, Therapy-Resistant,Depressions, Treatment Resistant,Depressive Disorder, Treatment Resistant,Depressive Disorders, Treatment-Resistant,Disorder, Treatment-Resistant Depressive,Disorders, Treatment-Resistant Depressive,Refractory Depressions,Resistant Depression, Treatment,Resistant Depressions, Treatment,Therapy Resistant Depression,Therapy-Resistant Depressions,Treatment Resistant Depressions,Treatment-Resistant Depressive Disorder,Treatment-Resistant Depressive Disorders

Related Publications

Taro Kishi, and Kenji Sakuma, and Yuki Matsuda, and Shinsuke Kito, and Nakao Iwata
January 2022, Frontiers in psychiatry,
Taro Kishi, and Kenji Sakuma, and Yuki Matsuda, and Shinsuke Kito, and Nakao Iwata
July 2023, Asian journal of psychiatry,
Taro Kishi, and Kenji Sakuma, and Yuki Matsuda, and Shinsuke Kito, and Nakao Iwata
September 2023, Psychiatry research,
Taro Kishi, and Kenji Sakuma, and Yuki Matsuda, and Shinsuke Kito, and Nakao Iwata
April 2022, The journals of gerontology. Series A, Biological sciences and medical sciences,
Taro Kishi, and Kenji Sakuma, and Yuki Matsuda, and Shinsuke Kito, and Nakao Iwata
September 2008, Canadian journal of psychiatry. Revue canadienne de psychiatrie,
Taro Kishi, and Kenji Sakuma, and Yuki Matsuda, and Shinsuke Kito, and Nakao Iwata
May 2009, Experimental brain research,
Taro Kishi, and Kenji Sakuma, and Yuki Matsuda, and Shinsuke Kito, and Nakao Iwata
April 2019, European journal of neurology,
Taro Kishi, and Kenji Sakuma, and Yuki Matsuda, and Shinsuke Kito, and Nakao Iwata
May 2021, Translational psychiatry,
Copied contents to your clipboard!